Table 1.

Patient demographics and disease characteristics at baseline

Variable	Total (n=101)		Cartinine (n=47)		Placebo (n=54)
	n	Percent	n	Percent	n	Percent
Age, yearsa	–	65 (39–84)	–	64 (42–83)	–	67 (39–84)
Male sex	45	44.6	16	34.0	29	53.7
Race
White	98	99.0	46	100.0	52	98.1
Black	1	1.0	0	0	1	1.9
Unknown	2	–	1	–	1	–
Ethnicity
Non-Hispanic or Latino	81	98.8	37	100.0	44	97.8
Hispanic or Latino	1	1.2	0	0	1	2.2
Unknown	19	–	10	–	9	–
ECOG performance status
0	32	31.7	16	34.0	16	29.6
1	57	56.4	27	57.5	30	55.6
2	12	11.9	4	8.5	8	14.8
Years since initial diagnosisa	89	0.8 (0.09–20.3)	41	0.7 (0.09–15.0)	48	0.8 (0.1–20.3)
Metastatic disease	48	47.5	25	53.2	23	42.6
Current cancer treatment
No current cancer therapy	18	17.8	4	8.5	11	20.4
Current radiotherapy only	8	7.9	3	6.4	6	11.1
Current chemo only	64	63.4	36	76.6	30	55.6
Both chemo and radiotherapy	11	10.9	4	8.5	7	13.0
Taking other medication at baseline
Psychostimulants	5	5.0	2	4.3	3	5.6
Analgesics	39	39.0	19	40.4	20	37.0
Antidepressants	33	32.7	14	29.8	19	35.2
Site of disease
Bone	2	2.4	0	0	2	3.7
Breast	26	29.6	16	34.0	10	18.5
Effusion/ascites	3	3.5	1	2.1	2	3.7
Gastrointestinal	17	19.8	7	14.9	10	18.5
Genitourinary	12	13.8	5	10.6	7	13.0
Head and neck	3	3.5	3	6.4	2	3.7
Liver	18	20.9	1	2.1	2	3.7
Lung	11	12.6	7	14.9	11	20.4
Nodes	22	25.6	3	6.4	8	14.8
Other	2	2.4	8	17.0	14	25.9
Hemoglobin, g/dL (mean, SD)	12.4	1.5	12.2	1.4	12.5	1.5
Hematocrit, % (mean, SD)	36.8	4.2	36.3	4.0	37.3	4.4
Iron, µg/dL (mean, SD)	80.7	47.8	71.6	44.3	88.9	49.9
Thyroid-stimulating hormone, µU/mL (mean, SD)	2.2	1.9	1.9	1.3	2.4	2.3

Note:

^aData presented as median (range).

Abbreviations: ECOG, Eastern Cooperative Oncology Group, SD, standard deviation.